+

WO1999041411A3 - Method for diagnosis and treatment of disorders of carbohydrate metabolism - Google Patents

Method for diagnosis and treatment of disorders of carbohydrate metabolism Download PDF

Info

Publication number
WO1999041411A3
WO1999041411A3 PCT/SE1999/000177 SE9900177W WO9941411A3 WO 1999041411 A3 WO1999041411 A3 WO 1999041411A3 SE 9900177 W SE9900177 W SE 9900177W WO 9941411 A3 WO9941411 A3 WO 9941411A3
Authority
WO
WIPO (PCT)
Prior art keywords
promoter
carbohydrate metabolism
patient
adenylate cyclase
relates
Prior art date
Application number
PCT/SE1999/000177
Other languages
French (fr)
Other versions
WO1999041411A2 (en
Inventor
Suad Efendic
Original Assignee
Suad Efendic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suad Efendic filed Critical Suad Efendic
Priority to JP2000531591A priority Critical patent/JP2002503483A/en
Priority to AU26512/99A priority patent/AU2651299A/en
Priority to EP99906659A priority patent/EP1053356A2/en
Priority to CA002319065A priority patent/CA2319065A1/en
Publication of WO1999041411A2 publication Critical patent/WO1999041411A2/en
Publication of WO1999041411A3 publication Critical patent/WO1999041411A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0393—Animal model comprising a reporter system for screening tests
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to a method of detecting a disorder in carbohydrate metabolism, such as type II diabetes (NIDDM), by detecting a promoter of an adenylate cyclase III gene, the promoter having enhanced activity. The present invention also relates to a promoter from an adenylate cyclase III gene having enhanced activity, and isolated DNA molecules containing this promoter. The promoter having enhanced activity can be part of a transgenic animal. In another embodiment, the invention relates to a method of treating a patient having a disorder in carbohydrate metabolism, such as type II diabetes (NIDDM), and a method of enhancing or restoring a patient's response to insulin. Each of these methods includes administering to the patient a down regulator, an antagonist, or an inhibitor of expression of the adenylate cyclase III gene, or of the activity of one of its gene products.
PCT/SE1999/000177 1998-02-11 1999-02-11 Method for diagnosis and treatment of disorders of carbohydrate metabolism WO1999041411A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2000531591A JP2002503483A (en) 1998-02-11 1999-02-11 Methods of diagnosing and treating glucose metabolism disorders
AU26512/99A AU2651299A (en) 1998-02-11 1999-02-11 Method for diagnosis and treatment of disorders of carbohydrate metabolism
EP99906659A EP1053356A2 (en) 1998-02-11 1999-02-11 Method for diagnosis and treatment of disorders of carbohydrate metabolism
CA002319065A CA2319065A1 (en) 1998-02-11 1999-02-11 Method for diagnosis and treatment of disorders of carbohydrate metabolism

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7442798P 1998-02-11 1998-02-11
US60/074,427 1998-02-11

Publications (2)

Publication Number Publication Date
WO1999041411A2 WO1999041411A2 (en) 1999-08-19
WO1999041411A3 true WO1999041411A3 (en) 1999-09-30

Family

ID=22119512

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1999/000177 WO1999041411A2 (en) 1998-02-11 1999-02-11 Method for diagnosis and treatment of disorders of carbohydrate metabolism

Country Status (5)

Country Link
EP (1) EP1053356A2 (en)
JP (1) JP2002503483A (en)
AU (1) AU2651299A (en)
CA (1) CA2319065A1 (en)
WO (1) WO1999041411A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994014427A2 (en) * 1992-12-23 1994-07-07 Zymogenetics, Inc. Use of skyrin and analogues for the treatment of diabetes mellitus and process for their preparation
WO1996036641A1 (en) * 1995-05-19 1996-11-21 The Johns Hopkins University School Of Medicine Susceptibility gene for obesity and type ii diabetes mellitus
WO1997004331A1 (en) * 1995-07-20 1997-02-06 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services System and method for performing in vivo imaging and oxymetry and ft microscopy by pulsed radiofrequency electron paramagnetic resonance

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994014427A2 (en) * 1992-12-23 1994-07-07 Zymogenetics, Inc. Use of skyrin and analogues for the treatment of diabetes mellitus and process for their preparation
WO1996036641A1 (en) * 1995-05-19 1996-11-21 The Johns Hopkins University School Of Medicine Susceptibility gene for obesity and type ii diabetes mellitus
WO1997004331A1 (en) * 1995-07-20 1997-02-06 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services System and method for performing in vivo imaging and oxymetry and ft microscopy by pulsed radiofrequency electron paramagnetic resonance

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ABDEL-HALIM S ET AL: "Mutations in the promoter of adenyl cyclase (AC)-III gene, overexpression of AC-III mRNA, and enhanced cAMP generation in Islets from the spontaneously diabetic GK RAT Model of Type 2 Diabetes", DIABETES, vol. 47, no. 3, March 1998 (1998-03-01), pages 498 - 504, XP002110194 *

Also Published As

Publication number Publication date
WO1999041411A2 (en) 1999-08-19
JP2002503483A (en) 2002-02-05
CA2319065A1 (en) 1999-08-19
AU2651299A (en) 1999-08-30
EP1053356A2 (en) 2000-11-22

Similar Documents

Publication Publication Date Title
Van Dop et al. ADP-ribosylation of transducin by pertussis toxin blocks the light-stimulated hydrolysis of GTP and cGMP in retinal photoreceptors.
Plamondon et al. Mutually protective actions of kainic acid epileptic preconditioning and sublethal global ischemia on hippocampal neuronal death: involvement of adenosine A1 receptors and KATP channels
Neuenschwander et al. Long-range synchronization of oscillatory light responses in the cat retina and lateral geniculate nucleus
Diamond Phenylalanine levels of 6‐10mg/dl may not be as benign as once thought
Rada et al. Galanin in the hypothalamus raises dopamine and lowers acetylcholine release in the nucleus accumbens: a possible mechanism for hypothalamic initiation of feeding behavior
EP0788307A4 (en) Oligonucleotide modulation of multidrug resistance-associated protein
Li et al. Modulation of parabrachial taste neurons by electrical and chemical stimulation of the lateral hypothalamus and amygdala
WO2005027839A3 (en) Methods and reagents for the treatment of immunoinflammatory disorders
WO2005037203A3 (en) Methods and reagents for the treatment of immunoinflammatory disorders
WO2000038666A3 (en) A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES
Wand et al. Chronic ethanol treatment increases expression of inhibitory G-proteins and reduces adenylylcyclase activity in the central nervous system of two lines of ethanol-sensitive mice.
Yasoshima et al. Rat gustatory memory requires protein kinase C activity in the amygdala and cortical gustatory area
WO2003085093A3 (en) Antibodies that specifically bind to gmad
WO2000009754A3 (en) HUMAN STEAROYL-CoA DESATURASE-RELATED COMPOSITIONS AND METHODS FOR TREATING SKIN DISORDERS
Fazan Jr et al. Sildenafil acts on the central nervous system increasing sympathetic activity
DK0655926T3 (en) New probe for tumor diagnosis or tumor therapy
Mundinger et al. Short-term diabetic hyperglycemia suppresses celiac ganglia neurotransmission, thereby impairing sympathetically mediated glucagon responses
Ota et al. TPA-induced neurite formation in a neuroblastoma cell line (SH-SY5Y) is associated with increased IGF-I receptor mRNA and binding
WO1999041411A3 (en) Method for diagnosis and treatment of disorders of carbohydrate metabolism
Ninomiya et al. Enhanced responses of the chorda tympani nerve to nonsugar sweeteners in the diabetic db/db mouse
AU2932100A (en) Neurodegenerative disorder related gene
Morimoto et al. Conditional activation of cAMP signal transduction by protein kinase C. The effect of phorbol esters on adenylyl cyclase in permeabilized and intact cells.
WO2004016753A3 (en) Antibodies that immunospecifically bind to trail receptors
WO2005018536A3 (en) Agonist antibodies that specifically bind the glucagon like peptide-1 receptor
Szentirmai et al. Growth hormone-releasing hormone: cerebral cortical sleep-related EEG actions and expression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2319065

Country of ref document: CA

Ref country code: CA

Ref document number: 2319065

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999906659

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 09600378

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999906659

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999906659

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载